Vitamin D analogues to target residual proteinuria: Potential impact on cardiorenal outcomes

Nephrology Dialysis Transplantation

Volumn 30, Issue 12, 2015, Pages 1988-1994

  Humalda, Jelmer K ^a   Goldsmith, David J A ^b   Thadhani, Ravi ^c   De Borst, Martin H ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cardiovascular Disease; Chronic Kidney Disease; Proteinuria; Vitamin D

Indexed keywords

ALISKIREN; ATRASENTAN; CALCITRIOL; COLECALCIFEROL; PARICALCITOL; VITAMIN D DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VITAMIN D;

ARTICLE; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GLOMERULUS FILTRATION RATE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SODIUM INTAKE; TREATMENT PLANNING; CARDIO-RENAL SYNDROME; DRUG EFFECTS; RENAL INSUFFICIENCY, CHRONIC;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIO-RENAL SYNDROME; HUMANS; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; VITAMIN D;

EID: 84947567128     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu404     Document Type: Article

References (50)

1. Turin TC, James M, Ravani P et al. Proteinuria and rate of change in kidney function in a community-based population. J Am Soc Nephrol 2013; 24: 1661-1667
2. McQuarrie EP, Traynor JP, Taylor AH et al. Association between urinary sodium, creatinine, albumin, and long-Term survival in chronic kidney disease. Hypertension 2014; 64: 111-117
3. Fox CS, Matsushita K, Woodward M et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A meta-Analysis. Lancet 2012; 380: 1662-1673
4. Mahmoodi BK, Matsushita K, Woodward M et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: A meta-Analysis. Lancet 2012; 380: 1649-1661
5. Hillege HL, Fidler V, Diercks GF et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782
6. Holtkamp FA, de Zeeuw D, de Graeff PA et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: A post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J 2011; 32: 1493-1499
7. Schmieder RE, Mann JF, Schumacher H et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22: 1353-1364
8. Ruggenenti P, Perna A, Loriga G et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005; 365: 939-946
9. Ruggenenti P, Perna A, Remuzzi G et al. Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int 2003; 63: 2254-2261
10. Kunz R, Friedrich C, Wolbers M et al. Meta-Analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30-48
11. Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553
12. Parving HH, Brenner BM, McMurray JJ et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-2213
13. Fried LF, Emanuele N, Zhang JH et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369: 1892-1903
14. de Zeeuw D, Coll B, Andress D et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 2014; 25: 1083-1093
15. LaClair RE, Hellman RN, Karp SL et al. Prevalence of calcidiol deficiency in CKD: A cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005; 45: 1026-1033
16. Doorenbos CR, de Cuba MM, Vogt L et al. Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease. J Steroid Biochem Mol Biol 2012; 128: 56-61
17. Powe CE, Evans MK, Wenger J et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 2013; 369: 1991-2000
18. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435
19. Goncalves JG, de Braganca AC, Canale D et al. Vitamin D deficiency aggravates chronic kidney disease progression after ischemic acute kidney injury. PLoS ONE 2014; 9: e107228
20. Mirkovic K, van den Born J, Navis G et al. Vitamin D in chronic kidney disease: new potential for intervention. Curr Drug Targets 2011; 12: 42-53
21. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: 1070-1078
22. Shoben AB, Rudser KD, de Boer IH et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19: 1613-1619
23. de Borst MH, Hajhosseiny R, Tamez H et al. Active vitamin D treatment for reduction of residual proteinuria: A systematic review. J Am Soc Nephrol 2013; 24: 1863-1871
24. de Borst MH, Vervloet MG, ter Wee PM et al. Cross talk between the renin-Angiotensin-Aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol 2011; 22: 1603-1609
25. Yilmaz MI, Sonmez A, Saglam M et al. Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy. Am J Nephrol 2014; 40: 208-214
26. de Seigneux S, Courbebaisse M, Rutkowski JM et al. Proteinuria increases plasma phosphate by altering its tubular handling. J Am Soc Nephrol 2015; 26: 1608-1618
27. Yuan W, Pan W, Kong J et al. 1, 25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007; 282: 29821-29830
28. Li YC, Kong J, Wei M et al. 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-Angiotensin system. J Clin Invest 2002; 110: 229-238
29. Forman JP, Williams JS, Fisher ND. Plasma 25-hydroxyvitamin D and regulation of the renin-Angiotensin system in humans. Hypertension 2010; 55: 1283-1288
30. Thadhani R, Appelbaum E, Pritchett Y et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial. JAMA 2012; 307: 674-684
31. Ito I, Waku T, Aoki M et al. A nonclassical vitamin D receptor pathway suppresses renal fibrosis. J Clin Invest 2013; 123: 4579-4594
32. Andrukhova O, Slavic S, Zeitz U et al. Vitamin D is a regulator of endothelial nitric oxide synthase and arterial stiffness in mice. Mol Endocrinol 2014; 28: 53-64
33. Zoccali C, Curatola G, Panuccio V et al. Paricalcitol and endothelial function in chronic kidney disease trial. Hypertension 2014; 64: 1005-1011
34. Molina P, Gorriz JL, Molina MD et al. The effect of cholecalciferol for lowering albuminuria in chronic kidney disease: A prospective controlled study. Nephrol Dial Transplant 2014; 29: 97-109
35. Brandenburg VM, Floege J. Adynamic bone disease-bone and beyond. NDT Plus 2008; 1: 135-147
36. Zoccali C, Ruggenenti P, Perna A et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol 2011; 22: 1923-1930
37. Floege J, Kim J, Ireland E et al. SerumiP TH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011; 26: 1948-1955
38. Mazzaferro S, Goldsmith D, Larsson TE et al. Vitamin D metabolites and/or analogs: which D for which patient? Curr Vasc Pharmacol 2014; 12: 339-349
39. Drechsler C, Pilz S, Obermayer-Pietsch B et al. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J 2010; 31: 2253-2261
40. Autier P, Gandini S. Vitamin D supplementation and total mortality: A meta-Analysis of randomized controlled trials. Arch Intern Med 2007; 167: 1730-1737
41. Hsia J, Heiss G, Ren H et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007; 115: 846-854
42. Tamez H, Zoccali C, Packham D et al. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J 2012; 164: 902-9.e2
43. de Zeeuw D, Agarwal R, Amdahl M et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial. Lancet 2010; 376: 1543-1551
44. Humalda JK, Navis G. Dietary sodium restriction: A neglected therapeutic opportunity in chronic kidney disease. Curr Opin Nephrol Hypertens 2014; 23: 533-540
45. Joosten MM, Gansevoort RT, Mukamal KJ et al. Sodium excretion and risk of developing coronary heart disease. Circulation 2014; 129: 1121-1128
46. McMahon EJ, Bauer JD, Hawley CM et al. A randomized trial of dietary sodium restriction in CKD. J Am Soc Nephrol 2013; 24: 2096-2103
47. Fan L, Tighiouart H, Levey AS et al. Urinary sodium excretion and kidney failure in nondiabetic chronic kidney disease. Kidney Int 2014; 86: 582-588
48. ODonnell M, Mente A, Rangarajan S et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med 2014; 371: 612-623
49. Cook NR, Cutler JA, Obarzanek E et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007; 334: 885-888
50. Laverman GD, de Zeeuw D, Navis G. Between-patient differences in the renal response to renin-Angiotensin system intervention: clue to optimising renoprotective therapy? J Renin Angiotensin Aldosterone Syst 2002; 3: 205-213